Catcher Technology (2474) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
31 Mar, 2026Executive summary
Revenue for 4Q24 was NT$4.636bn, down 9.4% sequentially but up 40.2% year-over-year due to a low base.
Full-year 2024 revenue reached NT$18.084bn, a 0.1% increase year-over-year, reflecting demand recovery.
Net profit after tax (NPAT) for 4Q24 was NT$3.758bn, up 162.8% sequentially and returning to profitability year-over-year.
Net profit for 2024 surged 44% year-over-year to NT$13.20bn, with total comprehensive income at NT$16.80bn.
Basic EPS for 2024 was NT$19.40, up from NT$13.33 in 2023.
Consolidated financial statements audited with an unmodified opinion, confirming fair presentation in accordance with IFRS and local regulations.
Financial highlights
4Q24 gross margin was 32.1%, down 2.4pp sequentially but up 7.4pp year-over-year; full-year gross margin improved to 32% from 27% in 2023.
Operating margin for 4Q24 was 18.5%, down 4.9pp sequentially and up 16.9pp year-over-year; full-year operating margin was 18% vs. 9% in 2023.
Net FX gains in 4Q24 were NT$1.923bn; full-year FX gains were NT$4.045bn.
EBITDA for 2024 was NT$5.171bn, up from NT$4.407bn in 2023.
Cash and cash equivalents increased to NT$50.36bn at year-end 2024 from NT$42.46bn in 2023.
Outlook and guidance
Board resolved to pay cash dividends of NT$7.5 per share from 1H24 earnings, with a 64% payout ratio.
Annual cash dividends have exceeded 60% payout in the past three years, with a yield of 4-6% from 2015-2023.
Management continues to assess the impact of new and upcoming IFRS standards, including IFRS 18 and 19, with further disclosures to follow.
Latest events from Catcher Technology
- H1 2024 net profit rose 49% despite a 20% revenue drop, supported by FX gains and strong liquidity.2474
Q2 202431 Mar 2026 - Q3 2024 revenue and margins rose, but net profit and cash fell amid FX losses and capital returns.2474
Q3 202431 Mar 2026 - Gross margin reached 35% as revenue grew 18.9% year-over-year, but net profit fell sharply.2474
Q1 202531 Mar 2026 - 2Q25 revenue increased, but FX losses and margin pressure led to a net loss; diversification continues.2474
Q2 202531 Mar 2026 - 3Q25 net profit more than doubled year-over-year despite a 5% revenue decline.2474
Q3 202531 Mar 2026 - 4Q25 revenue fell, but gross margin rose; 2025 profit and EPS dropped despite medtech growth.2474
Q4 202531 Mar 2026